Gene Review:
gag-pol - Gag-Pol
Human immunodeficiency virus 1
Patterson,
Carlo,
Kaplan,
Marecki,
Pawha,
Moss,
Parveen,
Mukhtar,
Goodrich,
Acheampong,
Dornburg,
Pomerantz,
Otten,
Schaefer,
Doe,
Liu,
Megede,
Donnelly,
Rabussay,
Barnett,
Ulmer,
Graham,
Koup,
Roederer,
Bailer,
Enama,
Moodie,
Martin,
McCluskey,
Chakrabarti,
Lamoreaux,
Andrews,
Gomez,
Mascola,
Nabel,
Sei,
Yang,
O'Neill,
Yoshimura,
Nagashima,
Mitsuya,
- Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. Sei, S., Yang, Q.E., O'Neill, D., Yoshimura, K., Nagashima, K., Mitsuya, H. J. Virol. (2000)
- Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein. Liu, H., Wu, X., Xiao, H., Conway, J.A., Kappes, J.C. J. Virol. (1997)
- Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. Wu, X., Liu, H., Xiao, H., Conway, J.A., Hehl, E., Kalpana, G.V., Prasad, V., Kappes, J.C. J. Virol. (1999)
- Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Yung, E., Sorin, M., Pal, A., Craig, E., Morozov, A., Delattre, O., Kappes, J., Ott, D., Kalpana, G.V. Nat. Med. (2001)
- Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Jacks, T., Power, M.D., Masiarz, F.R., Luciw, P.A., Barr, P.J., Varmus, H.E. Nature (1988)
- Complementation of integrase function in HIV-1 virions. Fletcher, T.M., Soares, M.A., McPhearson, S., Hui, H., Wiskerchen, M., Muesing, M.A., Shaw, G.M., Leavitt, A.D., Boeke, J.D., Hahn, B.H. EMBO J. (1997)
- The cellular HIV-1 Rev cofactor hRIP is required for viral replication. Yu, Z., Sánchez-Velar, N., Catrina, I.E., Kittler, E.L., Udofia, E.B., Zapp, M.L. Proc. Natl. Acad. Sci. U.S.A. (2005)
- Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Seth, A., Ourmanov, I., Kuroda, M.J., Schmitz, J.E., Carroll, M.W., Wyatt, L.S., Moss, B., Forman, M.A., Hirsch, V.M., Letvin, N.L. Proc. Natl. Acad. Sci. U.S.A. (1998)
- In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Lindhofer, H., von der Helm, K., Nitschko, H. Virology (1995)
- An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Ashorn, P., McQuade, T.J., Thaisrivongs, S., Tomasselli, A.G., Tarpley, W.G., Moss, B. Proc. Natl. Acad. Sci. U.S.A. (1990)
- Saquinavir. Clinical pharmacology and efficacy. Vella, S., Floridia, M. Clinical pharmacokinetics. (1998)
- Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. Luque, I., Todd, M.J., Gómez, J., Semo, N., Freire, E. Biochemistry (1998)
- Binding of oligopyrimidines to the RNA hairpin responsible for the ribosome gag-pol frameshift in HIV-1. Aupeix, K., Le Tinévez, R., Toulmé, J.J. FEBS Lett. (1999)
- Evidence for the differential effects of nucleocapsid protein on strand transfer in various regions of the HIV genome. Derebail, S.S., Heath, M.J., DeStefano, J.J. J. Biol. Chem. (2003)
- Helper plasmids for production of HIV-1-derived vectors. Fuller, M., Anson, D.S. Hum. Gene Ther. (2001)
- Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Otten, G.R., Schaefer, M., Doe, B., Liu, H., Megede, J.Z., Donnelly, J., Rabussay, D., Barnett, S., Ulmer, J.B. Vaccine (2006)
- Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1. Paulus, C., Ludwig, C., Wagner, R. Virology (2004)
- Phosphorylation of HIV-1 gag proteins by protein kinase C. Burnette, B., Yu, G., Felsted, R.L. J. Biol. Chem. (1993)
- The function of a ribosomal frameshifting signal from human immunodeficiency virus-1 in Escherichia coli. Yelverton, E., Lindsley, D., Yamauchi, P., Gallant, J.A. Mol. Microbiol. (1994)
- Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. Patterson, B.K., McCallister, S., Schutz, M., Siegel, J.N., Shults, K., Flener, Z., Landay, A. AIDS (2001)
- Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen. Patterson, B.K., Carlo, D.J., Kaplan, M.H., Marecki, M., Pawha, S., Moss, R.B. AIDS (1999)
- Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing. Lange-Savage, G., Berchtold, H., Liesum, A., Budt, K.H., Peyman, A., Knolle, J., Sedlacek, J., Fabry, M., Hilgenfeld, R. Eur. J. Biochem. (1997)
- Role of RNA in facilitating Gag/Gag-Pol interaction. Khorchid, A., Halwani, R., Wainberg, M.A., Kleiman, L. J. Virol. (2002)
- Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. Reicin, A.S., Paik, S., Berkowitz, R.D., Luban, J., Lowy, I., Goff, S.P. J. Virol. (1995)
- Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. Iga, M., Matsuda, Z., Okayama, A., Sugiura, W., Hashida, S., Morishita, K., Nagai, Y., Tsubouchi, H. J. Virol. Methods (2002)
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine. Graham, B.S., Koup, R.A., Roederer, M., Bailer, R.T., Enama, M.E., Moodie, Z., Martin, J.E., McCluskey, M.M., Chakrabarti, B.K., Lamoreaux, L., Andrews, C.A., Gomez, P.L., Mascola, J.R., Nabel, G.J. J. Infect. Dis. (2006)
- Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. Bardy, M., Gay, B., Pébernard, S., Chazal, N., Courcoul, M., Vigne, R., Decroly, E., Boulanger, P. J. Gen. Virol. (2001)
- Cells surviving infection by human immunodeficiency virus type 1: vif or vpu mutants produce non-infectious or markedly less cytopathic viruses. Kishi, M., Nishino, Y., Sumiya, M., Ohki, K., Kimura, T., Goto, T., Nakai, M., Kakinuma, M., Ikuta, K. J. Gen. Virol. (1992)
- A new-generation stable inducible packaging cell line for lentiviral vectors. Farson, D., Witt, R., McGuinness, R., Dull, T., Kelly, M., Song, J., Radeke, R., Bukovsky, A., Consiglio, A., Naldini, L. Hum. Gene Ther. (2001)
- Discovery and analysis of a series of C2-symmetric HIV-1 proteinase inhibitors derived from penicillin. Gray, N.M., Cameron, J.M., Cammack, N., Cobley, K.N., Holmes, D.S., Humber, D.C., Orr, D.C., Penn, C.R., Potter, R., Madar, S. Anal. Biochem. (1994)
- Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. Gupta, P., Collins, K.B., Ratner, D., Watkins, S., Naus, G.J., Landers, D.V., Patterson, B.K. J. Virol. (2002)
- Cross-packaging of human immunodeficiency virus type 1 vector RNA by spleen necrosis virus proteins: construction of a new generation of spleen necrosis virus-derived retroviral vectors. Parveen, Z., Mukhtar, M., Goodrich, A., Acheampong, E., Dornburg, R., Pomerantz, R.J. J. Virol. (2004)